Why the study?
Does antiplatelet monotherapy with ticagrelor lower bleeding while maintaining ischemic efficacy compared to standard therapy in selected patients undergoing PCI?
Does antiplatelet monotherapy with ticagrelor lower bleeding while maintaining ischemic efficacy compared to standard therapy in selected patients undergoing PCI?
Answers are grounded in this paper and cite their sources.
Aspirin monotherapy is losing favor for both primary and secondary prevention, while ticagrelor monotherapy is emerging as a strategy to reduce bleeding risk without compromising ischemic protection after PCI.
In the contemporary era, routine use of aspirin is not beneficial in the majority of patients free of cardiac disease. In contrast, for secondary prevention, aspirin monotherapy is not sufficient to lower recurrent vascular risk. Antiplatelet monotherapy with ticagrelor may emerge as an alternative to lower bleeding whereas maintaining ischemic efficacy in selected patients undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Goel et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: